Free Trial
NASDAQ:VIVS

VivoSim Labs 8/12/2025 Earnings Report

$2.51 +0.25 (+11.06%)
As of 09/5/2025 04:00 PM Eastern

VivoSim Labs EPS Results

Actual EPS
-$1.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

VivoSim Labs Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

VivoSim Labs Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

VivoSim Labs Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
See More VivoSim Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VivoSim Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VivoSim Labs and other key companies, straight to your email.

About VivoSim Labs

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

View VivoSim Labs Profile

More Earnings Resources from MarketBeat